Dupilumab-associated arthralgia: an observational retrospective study in VigiBase ®

Br J Dermatol. 2021 Apr 7. doi: 10.1111/bjd.20138. Online ahead of print.ABSTRACTDear Editor, Dupilumab is a human monoclonal antibody that blocks the shared receptor unit for interleukin (IL)-4 and IL-13, and is approved in several indications, including moderate-to-severe atopic dermatitis (AD). According to a recent meta-analysis dupilumab treatment versus placebo resulted in a significant increase in the number of patients who achieved Eczema Area and Severity Index-75 (Rate-Ratio 3.09; 95% CI 2.45-3.89) in different ethnical populations.PMID:33829495 | DOI:10.1111/bjd.20138

Source: The British Journal of Dermatology - April 8, 2021 Category: Dermatology Authors: B Chr étien C Dolladille J Alexandre S Fedrizzi V Lelong-Boulouard J C Lambert E Ezine Source Type: research